Increasing evidence implicates mitochondrial dysfunction in aging and age-related conditions. But little is known about the molecular basis for this connection. A possible cause may be mutations in the mitochondrial DNA (mtDNA), which are often heteroplasmic-the joint presence of different alleles at a single locus in the same individual. However, the involvement of mtDNA heteroplasmy in aging and age-related conditions has not been investigated thoroughly. We deep-sequenced the complete mtDNA genomes of 356 Framingham Heart Study participants (52% women, mean age 43, mean coverage 4570-fold), identified 2880 unique mutations and comprehensively annotated them by MITOMAP and PolyPhen-2. We discovered 11 heteroplasmic "hot" spots [NADH dehydrogenase (ND) subunit 1, 4, 5 and 6 genes, n = 7; cytochrome c oxidase I (COI), n = 2; 16S rRNA, n = 1; D-loop, n = 1] for which the alternative-to-reference allele ratios significantly increased with advancing age (Bonferroni correction p < 0.001). Four of these heteroplasmic mutations in ND and COI genes were predicted to be deleterious nonsynonymous mutations which may have direct impact on ATP production. We confirmed previous findings that healthy individuals carry many low-frequency heteroplasmy mutations with potentially deleterious effects. We hypothesize that the effect of a single deleterious heteroplasmy may be minimal due to a low mutant-to-wildtype allele ratio, whereas the aggregate effects of many deleterious mutations may cause changes in mitochondrial function and contribute to age-related diseases. The identification of age-related mtDNA mutations is an important step to understand the genetic architecture of age-related diseases and may uncover novel therapeutic targets for such diseases.
Introduction
In humans, mitochondria produce energy for most cellular activities through oxidative phosphorylation (OXPHOS) and play essential roles in regulating many cellular processes (Wallace 2005; Voet and Pratt 2006) . Mitochondria contain their own DNA (mtDNA), a circular genome of approximately 16.6 kb that is exclusively inherited maternally. The mtDNA encodes 13 key OXPHOS complex proteins and 22 tRNA and 2 rRNA genes for mitochondrial protein translation (Voet and Pratt 2006) . Due to a limited repair capacity, mutations occur with greater frequency in the mtDNA compared to the nuclear genome (nDNA) (Wallace 1994) . Cells contain many mitochondria with each mitochondrion containing 5-10 copies of mtDNA. Therefore, mtDNA mutations are often heteroplasmic, a condition whereby different mtDNA variants co-exist within a cell or across cells (Tuppen et al. 2010) .
Mitochondrial functions gradually deteriorate during normal aging (Payne and Chinnery 2015) , and is considered one of the hallmarks of aging (Lopez-Otin et al. 2013 ). Wallace reported the first evidence in humans that mutations in mtDNA may cause human multisystem disorders that parallel aging (Wallace 2005) . High levels of mtDNA mutations have been found in skeletal muscles of old monkeys (Schwarze et al. 1995) , livers of old mice (Khaidakov et al. 2003) , and fibroblasts of older adults (Michikawa et al. 1999) . Two similar mouse models with a homozygous knock-in mutation for the error-prone mtDNA polymerase gene (the PolG mice) exhibited greatly increased accumulation of somatic mtDNA mutations, reduced lifespan, and premature aging phenotypes including reduced fertility, cardiomyopathy, and frailty (Kujoth et al. 2005; Trifunovic et al. 2004) . Several mtDNA mutations have been described to cause rare yet, severe diseases in human (Taylor and Turnbull 2005) . Accumulating evidence has also suggested that mtDNA mutations are involved in age-related common diseases such as cardiovascular disease and cancers (Wallace 2005; Tuppen et al. 2010; Taylor and Turnbull 2005; Seyfried 2015; Seyfried et al. 2015; Saxena et al. 2006; Liu et al. 2012; Byrne et al. 2009; Kang et al. 2016) . Replication of associations between homoplasmic mtDNA mutations and common diseases has proven difficult due to small sample sizes in previous studies or lack of replication samples (Saxena et al. 2006; Liu et al. 2012; Byrne et al. 2009 ). Establishing the role of heteroplasmic mtDNA variation in relation to complex phenotypes is still in its infancy and the genetic basis for the age-related decline in mitochondrial function remains unclear (Stewart and Chinnery 2015; Stefano and Kream 2016) . With the advent of next generation sequencing and reduced costs of whole-genome sequencing, it is now possible to study a spectrum of rare/low-frequency and heteroplasmic mtDNA variants in large sample sizes (He et al. 2010; Ding et al. 2015; Ye et al. 2014; Li et al. 2010; Payne et al. 2013) .
A few studies recently analyzed mtDNA mutations with whole-genome sequencing or mtDNA sequencing and reported that healthy individuals carry many heteroplasmic mutations (He et al. 2010; Ding et al. 2015; Ye et al. 2014; Li et al. 2010; Payne et al. 2013 ) that increase in prevalence with age (Ding et al. 2015) and are significantly overrepresented at known disease-associated loci (Ye et al. 2014) . Most reported heteroplasmic mutations, however, are rare and potentially enriched with deleterious mutations (Ye et al. 2014) . The high coverage and low error rate in sequence analysis of mtDNA are required to accurately identify mtDNA heteroplasmy. Therefore, it is essential to validate and extend previous findings and to discover further evidence for the role of mtDNA variation in aging and health. To that end, we analyzed the complete mtDNA genomes of 356 Framingham Heart Study (FHS) individuals using a deep sequencing method, mitoRCAseq (Ni et al. 2015) , which utilizes mtDNA-specific rolling circle amplification to enrich the full-length mtDNA to increase the coverage and decrease the contamination with nuclear-encoded mtDNA sequences. We aimed to identify and characterize a full spectrum of mtDNA point mutations and to extend findings of recent publications (He et al. 2010; Ding et al. 2015; Ye et al. 2014; Li et al. 2010; Payne et al. 2013 ). In addition, we sought to gain new insights into the role of mtDNA heteroplasmy in aging and health.
Methods

Study population
The design and recruitment of FHS three-generation cohorts have been described previously (Dawber et al. 1951; Feinleib et al. 1975; Splansky et al. 2007 ). All study participants have provided written consent for genetic research and cell line creation. The design of this study is detailed in Supplemental Data and illustrated in Supplemental Fig. 1 . This study used all three generational cohorts to construct maternal lineages (Liu et al. 2012) . We selected 400 individuals from independent lineages for mtDNA sequencing. After quality control procedures, 356 individuals (Supplemental Table 1 ) remained for analysis of mtDNA mutations with cell line-derived DNA.
mtDNA preparation and sequencing
The Offspring cohort participants had their blood drawn between 1998 and 2005 (around examination 7). The Third Generation cohort participants had their blood drawn at examination 1 (between 2002 and 2005) . Similar conditions were applied to Offspring and Third Generation cohort participants for blood draw, storage, cell line construction, and DNA extraction from cell lines.
The National Heart, Lung, and Blood Institute's DNA Sequencing and Genomics Core Facility performed mtDNA sequencing using the mitoRCA-seq approach (Ni et al. 2015) This strategy employed a rolling circle amplification (RCA) method to enrich full-length mtDNA molecules from genomic DNA for subsequent library construction. The main advantage of the mitoRCA-seq strategy is the enrichment of full-length mtDNA, thus minimizing contamination from the nuclear-encoded mtDNA sequences (Ni et al. 2015) . In addition, the mtRCA-seq used a high-fidelity enzyme, Phi29 DNA polymerase, for initial mtDNA enrichment. This enzyme has a low error rate of 1 in 10 6 -10 7 bases (Esteban et al. 1993) . The final mtDNA libraries were sequenced using the Illumina HiSeq-2000 platform.
Quality control
We focused on point mutations in this study. After de-multiplexing, raw sequencing reads were quality filtered with mapping quality score ≥ 30 to minimize potential sequencing errors (Ni et al. 2015) . Then, the raw reads were aligned to the human revised Cambridge Reference Sequence (rCRS) (Andrews et al. 1999) by Burrows-Wheeler Aligner (BWA) using default parameters (Li and Durbin 2009) . In parallel, we selected the read with the highest average quality score (defined as best-unique read) for raw reads sharing the same sequence. The resulting best-unique reads were used for downstream mutation calling. In addition, each mutation site was required to be supported by multiple best-unique reads to remove PCR amplification artifacts (Ni et al. 2015) .
We applied several additional filters to the mtDNA sequencing data. In an individual, we set the read as missing if a site had < 30 mapped reads. We calculated the sample coverage which was the mean coverage of all 16,569 mtDNA sits in an individual. We also calculated the locus coverage which was the mean coverage at a mtDNA site across all individuals. Using the rCRS sequence as the reference, we defined alternative allele frequency (AAF) at a given site, AAF site , which measured the proportion of alleles that were different from the reference allele over all mapped reads in an individual. Unlike the next generation sequencing that provides great depth of coverage, earlier genotyping arrays were not designed to discover heteroplasmic mutations. A low (e.g., 15%) or high (e.g., 85%) level heteroplasmic mutation is most likely to be identified as a homoplasmic for the reference allele or the variant allele by genotyping arrays. To compare with mtDNA alleles from previous genotyping, we used a relaxed threshold for assigning homoplasmic and heteroplasmic alleles for QC purposes: a site was deemed to be homoplasmic for the reference allele if the AAF site ≤ 25% at the site; a site to be homoplasmic for the alternative allele if the AAF site ≥ 75%; and a site was defined as heteroplasmic if AAF site was between 25 and 75%. We compared sequencingderived homoplasmic alleles to alleles called on two genotyping arrays. One array included 172 mtDNA variants from the Exome Chip which was designed to investigate rare/ low-frequency variants in the protein-coding regions (Grove et al. 2013) . The other array included 40 mtDNA variants genotyped on a customized platform (Liu et al. 2012) . Both the Exome Chip and 40-mtDNA arrays used DNA that was extracted from cell lines.
We excluded samples if (1) the sample mean coverage was less than 1000-fold (all mapped reads) or 100-fold (uniquely mapped reads), (2) samples displayed high alternative allele frequencies across many mtDNA loci, and (3) samples showed different homoplasmic alleles at multiple loci by comparing respective alleles called on array-based genotyping and derived on sequencing data.
Definition of homoplasmic and heteroplasmic mutations
To identify true heteroplasmic mutations, we used a more stringent cutoff to define mtDNA heteroplasmy with bestunique reads ≥ 30. We defined a site to be homoplasmic of the rCRS reference allele if its AAF site ≤ 5% (i.e., no mutation compared to rCRS reference allele) and a site to be homoplasmic for the alternative allele if its AAF site ≥ 95%. A site was called as heteroplasmic if its AAF site was between 5 and 95% and the heteroplasmic allele was observed in both forward and reverse strand sequence reads. For simplicity, we refer this cutoff as the "5_95% rule". We counted the number of heteroplasmic and homoplasmic mutations across the entire mtDNA per individual. We calculated the minor allele frequency (MAF) and the frequency of individuals displaying heteroplasmy (hetF) at each of the 16,569 mtDNA positions.
Bioinformatics analysis
The MITOMAP database provides an extensive compilation of human mtDNA mutations. We used MITOMASTER, a powerful sequence analysis tool, within MITOMAP to analyze and annotate the identified single nucleotide mutations (Lott et al. 2013) . In brief, MITOMASTER aligns mutation nucleotides to the rCRS and GeneBank protein-coding sequence data and reports information including mutation type (transition or transversion), gene locus, effect on amino acid change (synonymous, nonsynonymous or termination), any reported disease associated with the mutation. For nonsynonymous mutations, we employed PolyPhen-2 to predict if a variant has deleterious or damaging effects on protein function (Adzhubei et al. 2013 ). For all PolyPhen-2 functional predictions, the following UniProtKB ascension numbers were used to identify the OXPHOS protein subunits: ND1, P03886; ND2, P03891; ND3, P03897; ND4, P03897; ND4L, P03901; ND5, P03915; ND6, P03923; CYB, P00156; COX1, P00395; COX2, P00403; COX3, P00414; ATP6, P00846; ATP8, P03928.
Association analysis between age and heteroplasmic mutations
We tested if heteroplasmic mutations were related to age in two ways. First, we tested the association between age and the number of heteroplasmic mutations across individuals as a function of age. We performed inverse normal transformation on the number of heteroplasmic mutations in linear regression. Second, we tested if the AAF site as a function of age for common heteroplasmic mutations in > 10% individuals. The inverse normal transformed AAF site values were used as the dependent variables. In addition to testing the heteroplasmic mutations in relation to continuous age variable, we displayed the interquartile range of the number of heteroplasmic mutations or AAF site values in three age groups, < 40, 40-59, and ≥ 60 years.
Several selected mtDNA loci in whole blood-derived DNA Among these 356 individuals, 131 were recently wholegenome sequenced using the whole blood-derived DNA as part of the NHLBI Trans-Omics for Precision Medicine (TOPMed) Program. We compared several selected mtDNA loci between the cell line-derived DNA and whole bloodderived DNA samples in these 131 individuals. Sequencing and control of the mtDNA sequences in these 131 individuals were reported in detail in the Supplemental materials. To ensure that not all identified heteroplasmic mutations were near the beginning or the end of sequencing reads, we used Integrative Genomics Viewer (IGV, http://softw are.broad insti tute.org/softw are/igv/) to examine several DNA samples from both DNA sources for each of these heteroplasmic mutations.
Results
High mtDNA sequencing coverage
After completing all QC procedures, 356 individuals remained eligible for analyses (see Supplemental Data for QC details). All 16,569 mtDNA positions had quality reads to define mutations. The total raw reads was 961,896,903, the mapped reads was 595,007,422 (i.e., the mapping percentage was 61.86%), and the uniquely mapped reads was 594,699,686. The mean coverage was 4570-fold using raw mapped reads and 261-fold using the best-unique reads across the mtDNA genome in 356 individual (Supplemental Fig. 2 ). The AAF site derived from all mapped reads was highly correlated (Pearson correlation = 0.98) to that from the best-unique reads. Owing to this high correlation, we report mutations that were based on best-unique reads (≥ 30).
mtDNA mutations overrepresented by rare heteroplasmic mutations
Based on comparison to rCRS, we identified 2880 mutations with the 5-95% rule, including 1931 (67.0%) heteroplasmic sites, 477 (16.6%) homoplasmic sites, and 472 (16.4%) "mixed" sites that were homoplasmic in some individuals but heteroplasmic in other individuals (Fig. 1a) . Most (n = 1415, 73%) heteroplasmic mutations were singletons, 437 (23%) were observed in 2-10 individuals, 48 (2%) were found in 11-36 individuals; and 31 (2%) were common mutations present in > 36 individuals (i.e., 10% of study participants or hetF > 10%) (Fig. 1b) . A total of 7587 heteroplasmic variants were present at 1931 heteroplasmic sites in 356 individuals. We further investigated the AAF site levels for these 7587 heteroplasmic mutations. Most heteroplasmic mutations were low-level AAF site mutations: 5351 (71%) with 5 < AAF site ≤ 10% and 1403 (19%) with 10 < AAF site ≤ 25%. Only 570 (8%) were mediumlevel (25 < AAF site ≤ 75%) and 263 (4%) were high-level (75 < AAF site < 95%) heteroplasmic mutations (Fig. 1c) . The singleton heteroplasmic mutations displayed a wide range of AAF site (5-95%). In contrast, 30 common heteroplasmic mutations were low-level (5 < AAF site < 25%) mutations except for T310C in the D-loop, which displayed a wide range of AAF site (9-71%) ( Fig. 2 and Supplemental  Fig. 3) . 
Common heteroplasmic mutations in the NADH dehydrogenase genes and the D-loop
We further investigated the 31 common heteroplasmic mutations that were shared by more than 10% individuals. Eleven of them were located in NADH dehydrogenase (ND) genes, ten in the D-loop (9 in the hypervariable region II), five in cytochrome c oxidase genes (n = 5), three in rRNAs and two in tRNA genes (Fig. 2, Supplemental Table 2 ). The three most common heteroplasmic mutations in ND genes were T10941G (L61R in ND4), which was shared by > 72% of individuals, A4256T (Q317L in ND1), which was shared by 62% of individuals, and T14132C (L599P in ND5), which was shared by 48% of individuals. Within the hypervariable region II of the D-loop, C309T and T310C in HVR2 were heteroplasmic in all individuals. Two additional loci in the same area, A302C and G316C, were heteroplasmic in > 90% individuals. Two heteroplasmic mutations in rRNA genes were shared by > 35% individuals. The heteroplasmic mutations in the cytochrome c oxidase genes and tRNA genes were shared by 10-20% of individuals (Supplemental Table 2 ).
We investigated the 31 common heteroplasmic mtDNA loci in sequences of 131 participants who also had whole blood-derived DNA samples sequenced (mean coverage 2338-fold). The three loci in the D-loop region were heteroplasmic in 46.6% (A302C), 56.6% (G316C), and 100% (T310C) of the 131 individuals of whole blood-derived DNA, nine loci were heteroplasmic in smaller numbers of individuals, but the remaining 19 loci were not variable in any of these 131 individuals (Supplemental Table 3 ). With IGV, we confirmed that these heteroplasmic mutations are likely reliable heteroplasmic mutations (Supplemental Fig. 4 ).However, caution should be exercised when interpreting their alternative allele frequencies because some alternative alleles were near the beginning or the end of sequencing reads (Supplemental Fig. 5 ).
Heteroplasmic mutations enriched in nonsynonymous deleterious mutations
We comprehensively annotated all 2880 mutations by MITOMAP (Lott et al. 2013 ) and PolyPhen-2 (Adzhubei et al. 2013) . Of all mutations, 321 sites were in the D-loop, 1917 sites in the 13 protein-encoding genes, 212 in 22 tRNAs, 405 in two rRNA genes, and 25 in intergenic regions (Table 1 and Supplemental Table 4 ).
Of the 1917 mutations in protein-coding genes, 722 (38%) were synonymous mutations, 1137 (59%) were nonsynonymous amino acid substitution mutations, 53 (2.7%) caused protein truncation (that is, a mutation that changes an amino acid codon to a stop codon), and five (0.3%) caused extension (that is, a mutation changes a stop codon to an amino acid codon; Supplemental Table 5 ). Most of the 53 truncation sites were low-level heteroplasmic mutations (AAF site : mean ± SD = 10.9 ± 8.7). Forty of these 53 mutations were singletons (i.e., observed in only one individual), and the rest were shared by two-ten individuals.
We predicted the effects of the 1137 amino acid substitution mutations (Adzhubei et al. 2013) : 389 (34%) were predicted to be benign (average prediction score = 0.05), 133 (12%) alleles were predicted to be "possibly damaging" (average prediction score = 0.77), 609 (53.7%) were predicted to be probably damaging (average prediction score = 0.99), and six (0.3%) had unknown effects (Adzhubei et al. 2013 ) (Supplemental Table 5 (Fig. 3a) .
Identified mutations enriched with known mtDNA-disease alleles
MITOMAP (Lott et al. 2013) annotation revealed that 3% of the 16,569 mtDNA sites have been reported in association with clinical conditions versus 195 of the 2880 mutations in this study (3 versus 7%, Fisher's exact p < 2.2 × 10 −16 ; Supplemental Table 6 ). Furthermore, we found that sites displaying both heteroplasmic and homoplasmic mutations were greatly overrepresented with disease-associated alleles (n = 53, 11%) compared to sites displaying heteroplasmy (n = 110, 6%, p = 6.2 × 10 −5 ) or homoplasmy (n = 32, 7%, p = 0.05; Fig. 3b ). We retrieved "conservation scores" that indicate the degree of conservation for genetic loci across species (Lott et al. 2013 ) for 2880 loci with an available "conservation score" (scores were not available for loci at D-loop). The average score was 64 for the 195 loci with known clinical conditions, which was lower than the average score of 71 for all identified loci (t test p = 0.008), indicating that the loci with known disease conditions are more mutable.
Imbalance transition to transversion ratio across mtDNA
The transition to transversion (Ti/Tv) ratio for these 2880 mutations was approximately 10. Of note, the ti/tv ratio was highly imbalanced across different regions: Ti/Tv = 4 in the D-loop, Ti/Tv = 12 in protein-coding genes, Ti/Tv = 23 in rRNA genes, Ti/Tv = 13 in tRNA genes, and Ti/Tv = 1.5 in the intergenic regions.
Deleterious nonsynonymous heteroplasmic variation increases with aging
For common heteroplasmic mutations that were shared in > 10% of individuals (Supplemental Table 2 ), we related alternative allele frequencies (i.e., inverse transformed AAF site levels) to age at the time of blood draw. Age was significantly associated with alternative allele frequencies at 11 heteroplasmic loci, including seven sites at ND genes, two sites at COI genes, one at the D-loop, and one at the 16s rRNA gene (p < 0.05/31 ~ 0.001, Table 2 ). The median and interquartile range of AAF site also displayed increases for these 11 heteroplasmic mutations across age groups < 40, 40-59, and ≥ 60 years (Fig. 4) . Sex was not significantly associated with alternative allele frequencies of the 11 mtDNA loci (Supplemental materials). Four of the 11 mutations were nonsynonymous and were predicted to be "probably or possibly damaging" by PolyPhen-2: three at ND genes including T10941G (p = 0.0002, L61R in ND4), T11678C (p = 5.2e−9, W307R in ND4), and T12506A (p = 1.1e−5, L57Q in ND5); one at G7065A (p = 0.0007, A388T in COI) ( Table 2) . Fig. 6a ). The maximum number of heteroplasmic mutations an individual carried was 105. The inverse normal transformed value of the number of heteroplasmic mutations was significantly associated with age (beta = 0.017, p = 3.4e−5) (Supplemental Fig. 6b ). On average, individuals > 60 years of age harbored 36 heteroplasmic mutations and individuals of < 40 years old had 26 mutations (Supplemental Fig. 7) .
Discussion
We used a robust mtDNA sequencing method, mitoRCAseq, which employs rolling circle amplification with mtDNA-specific primers to enrich the full-length circular mtDNA and to minimize the contamination of nuclearencoded mtDNA sequence (Ni et al. 2015) . This strategy substantially increased mtDNA sequencing specificity and coverage, and greatly improved the accuracy for detecting heteroplasmic mutations with low-level alternative allele frequencies compared to several recent studies that analyzed mtDNA mutations using whole-genome sequencing data or shallower mtDNA sequencing (He et al. 2010; Ding et al. 2015; Ye et al. 2014; Li et al. 2010; Payne et al. 2013) . With the mitoRCA-seq method, we acquired high mean coverage (4570-fold) across the entire mtDNA genome.
Our study identified several age-related heteroplasmic "hot" spots in mtDNA protein-coding genes, including the ND (complex 1) and COI (complex IV) genes. Strikingly, seven of 11 age-related heteroplasmic variants were in ND subunit genes. Complex I is the largest enzyme complex of the mitochondrial OXPHOS respiratory chain, transferring electrons to ubiquinone and generating a proton gradient across the mitochondrial inner member to drive ATP production (Berg et al. 2002) . Mutations in the mtDNA-encoded ND subunits lead to Complex I deficiencies, which have been found to cause the most common forms of OXPHOS dysfunctions and mitochondrial DNA diseases (Loeffen et al. 2000; Scaglia et al. 2004 ). We found two common deleterious nonsynonymous heteroplasmic mutations, T10941G and T11678C, that result in amino acid substitutions (L61R and W307R, respectively), replacing hydrophobic amino acids with the positively charged arginine in ND4 (Fig. 5) . Another deleterious heteroplasmy, T12506A, results in L57Q, replacing a hydrophobic amino acid with the polar amino acid glutamine in ND5. These three heteroplasmic mutations are located within or close to transmembrane domains of subunits ND4 (T10941G and T11678C) and ND5 (T12506A). The mtDNA-encoded subunits of Complex I are highly hydrophobic transmembrane proteins that form the proton pumping machinery (Potluri et al. 2004; Zickermann et al. 2009; Wirth et al. 2016) . The three deleterious nonsynonymous mutations in ND genes all replace hydrophobic amino acids with hydrophilic ones. Hence, these mutations likely alter the proton pumping ability of Fig. 4 The alternative allele frequencies of eleven mitochondrial DNA heteroplasmic mutations significantly associated with advancing age. Eleven loci included seven sites at NADH dehydrogenase genes, two sites at cytochrome oxidase I genes, one at the D-loop, and one at the 16s rRNA gene a key enzyme that impacts proton motive force and ATP production efficiency.
The creation of lymphoblastoid cell lines has provided a renewable source of DNA for many genotyping and sequencing projects, including the 1000 Genomes Project. A previous study found that cell line-derived DNA is an appropriate source for sequencing, while cell line transformation may introduce low-level de novo mutations (Londin et al. 2011 ). To date, the impact of cell line transformation on heteroplasmic mtDNA mutations has not been well studied. Although three loci in D-loop were common heteroplasmic mutations in both cell line-derived DNA and whole blood-derived DNA samples, the rest of the common heteroplasmic loci identified in cell line-based DNA samples were not variable or only heteroplasmic in smaller number of 131 individuals with whole blood DNA samples. Lower sequencing coverage of whole blood-derived DNA and enrichment of a single white blood cell type in cell line construction may be partly attributable to the observed differences. Nevertheless, our comparisons indicate that DNA sources have a big impact on heteroplasmic mtDNA mutations. Some caution should be exercised in generalizing our findings from cell line-derived DNA to whole blood-derived or other cell typederived DNA. Future systematic comparison of sequence variations for the entire mitochondrial genome in these 131 individuals with both types of DNA sources will shed light on the impact of cell line transformation on de novo mutations in mtDNA.
It is important to note that direct comparison of results between our study and several previous studies is impossible due to differences in DNA sources, sequencing coverage, allele frequency thresholds used to define mutations and heteroplasmy. For example, we identified several heteroplasmic mtDNA "hot" spots in the D-loop and in ND subunits, which were not reported in the study with much larger sample size but much lower sequencing coverage by Ding et al. (2015) . Nevertheless, we confirmed several previous findings. First, we found that the transition to transversion (Ti/Tv) ratio of the identified mtDNA mutations was approximate 10, which is similar to that reported in Ding et al. (2015) The highly variable Ti/Tv ratios across different mtDNA regions, however, are likely to result from mtDNA evolution and natural selection (Duchene et al. 2015) . Second, our investigation of the spectrum of mtDNA mutations confirmed that mtDNA mutations are overrepresented by rare heteroplasmic mutations across all regions of the mtDNA genome (He et al. 2010; Ding et al. 2015; Ye et al. 2014; Li et al. 2010; Payne et al. 2013 ). Third, we confirmed that the identified heteroplasmic mutations are overrepresented for known diseaseassociated sites (Ye et al. 2014) and are greatly enriched in deleterious mutations (Adzhubei et al. 2013) . Fourth, we observed that the number of heteroplasmic mutations per individual increased with advancing age, which is consistent with findings from Ding et al. (2015) and Kang et al. (2016) . Based on the fact that healthy individuals carry many low-frequency heteroplasmic mutations with potential deleterious effects, we hypothesize that the effect of a single deleterious heteroplasmy may be minimal due to a low mutant to wild-type ratio and that aggregate effects of many deleterious mutations may result in disease.
The identified mutation sites were overrepresented with known disease-associated sites, which is consistent with Ye (2014) . The known disease-associated sites showed significantly lower "conservation scores" than other identified loci, and therefore, tend to be more mutable. These findings demonstrate that people harboring homoplasmic or high-level heteroplasmic mtDNA disease-associated mutations may not develop mitochondrial diseases, which suggests that the mitochondrial genetic environment may play a key role compensating for mtDNA disease-associated mutations (Gaweda-Walerych and Zekanowski 2013; Kern and Kondrashov 2004) The notion that mitochondrial function declines with age (Wallace 2005; Wallace 2010 ) is supported by our observation that the number of heteroplasmic variants and their alternative allele frequencies increase with advancing age. The exact mechanism underlying the age-related decline in mitochondrial function, however, remains unclear. Accumulation of heteroplasmic mtDNA mutations as a function of age remains an important area of investigation.
Our study has several limitations. We applied a stringent threshold to define heteroplasmy and found 1931 heteroplasmic mutations with high-confidence, but on the other hand, we likely missed some low-level heteroplasmic mutations. We were unable to investigate mtDNA copy number due to the depletion of nuclear DNA to enrich full-length mtDNA molecules for sequencing specificity. We selected individuals from independent maternal lineages and therefore were not able to investigate germline mutations versus somatic mutations. Despite these limitations, we validated many previous findings and provided new evidence to support the notion that heteroplasmic mutations play important roles in age-related mitochondrial functional decline. Identification of age-related mitochondrial DNA mutations is one of the next steps to understand full genetic architecture of age-related diseases. Such studies may uncover novel therapeutic targets of age-related diseases, leading to strategies that slow down age-related changes and prevent multiple age-related diseases. URL MITOMAP: http://www.mitom ap.org/MITOM AP. PolyPhen-2: http://genet ics.bwh.harva rd.edu/pph2/.
